Newsletter

Menu

NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq

By Staff Correspondent |

France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to raise around $132 million. The company also intends to list as “GNFT” on the Nasdaq Global Market.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of the treatment for non-alcoholic steatohepatitis, or NASH, a type of fatty liver disease that is becoming common mainly due to the unhealthy food habits among the people. In the offering, the company intends to issue and sell about five million shares at $26.33 per share to investors. It also plans a private placement of its ordinary shares in Europe and other countries, simultaneously.

Genfit is looking to use $15 million of the proceeds from the offering to prepare for the commercialization of elafibranor, the drug candidate for NASH. Around $50 million will be used for the completion of the phase-III study of elafibranor and the further procedures – up to submission of new drug applications in the US and Europe. The company plans to use around $35 million of the remaining proceeds to initiate and complete the phase-III study of elafibranor for the treatment of primary biliary cholangitis.

An SEC filing by the company indicated last week that the main purpose of the offering is to take forward the development of its NASH drug

It is expected that the global offering and the private placement will close simultaneously on the third trading day after the final pricing and allocation of the offering.

Genfit is specialized in the development of drugs and diagnostic solutions for the treatment of various liver diseases. Elafibranor, the company’s lead drug candidate, has reached the final stages of development for the treatment of NASH, giving it an advantage over rivals. Recently, Genfit received FDA approval for the phase-II clinical trial of elafibranor for non-alcoholic steatohepatitis in children and adolescents.

Also read: Zynerba Pharmaceuticals receives US patent for its CBD gel

Meanwhile, the underwriters for the global offering have been granted a 30-day option to buy additional ADS and ordinary shares valued up to 15% of the total number of shares being offered. Excluding the underwriters’ option to purchase additional shares, the offering is expected to result in the dilution of about 14% of Genfit’s outstanding share capital.

After slipping to a two-year low in the final weeks of last year, Genfit shares have gained more than 40% on the Euronext Paris stock exchange. The stock is currently trading slightly below the levels seen a year earlier.

 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Advertisement

More on this Company

Extreme Networks Advances Cloud and AI Networking Strategy

January 28, 2026

Extreme Networks Beats Q2 Estimates, SaaS Growth Drives Top-Line Gains

January 28, 2026

AT&T Surpasses 2025 Targets, Signals Growth in 5G and Fiber

January 28, 2026

218 responses to “NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq”

  41. TMS System

    […]Wonderful story, reckoned we could combine a handful of unrelated data, nonetheless actually really worth taking a look, whoa did one find out about Mid East has got much more problerms also […]

  54. Upright Piano Moving

    […]Wonderful story, reckoned we could combine some unrelated information, nonetheless truly really worth taking a search, whoa did one particular study about Mid East has got additional problerms at the same time […]

  121. 늑대닷컴

    […]Wonderful story, reckoned we could combine several unrelated data, nevertheless seriously really worth taking a search, whoa did a single discover about Mid East has got extra problerms also […]

  145. ItMe.Xyz

    […]Wonderful story, reckoned we could combine several unrelated information, nevertheless definitely really worth taking a search, whoa did 1 find out about Mid East has got a lot more problerms also […]

  153. ItMe.Xyz

    […]Wonderful story, reckoned we could combine a few unrelated data, nevertheless definitely worth taking a appear, whoa did one particular study about Mid East has got a lot more problerms too […]

  155. seo wix

    […]we like to honor a lot of other net web sites on the internet, even if they aren’t linked to us, by linking to them. Beneath are some webpages worth checking out[…]

  165. clima en neza

    […]we prefer to honor quite a few other world wide web web sites on the net, even if they aren’t linked to us, by linking to them. Underneath are some webpages worth checking out[…]

  204. culiacan clima

    […]we like to honor a lot of other world-wide-web internet sites around the net, even if they aren’t linked to us, by linking to them. Below are some webpages really worth checking out[…]

Leave a Reply

Top